Canakinumab effective in treating systemic juvenile idiopathic arthritis
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisN Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
177 patients, suffering from systemic juvenile idiopathic arthritis (JIA) with active systemic features, who had been chosen to participate in two trials between July 2009 and December 2010, were randomised into two groups to either receive canakinumab or a placebo. Patients in Trial 1 received either canakinumab or the placebo for 29 days. Trial 2 incorporated a two-part withdrawal design, which ...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue